// App-Quantinova.ai

: Clinically significant improvements in patient-reported outcomes (PROs) in patients with a generalized pustular psoriasis (GPP) flare treated with spesolimab

Researchers

Presenter

  • Alexander A. Navarini

Principal Investigators

  • Manuelle Viguier

  • Tsen-Fang Tsai

  • Akimichi Morita

  • Jörg C. Prinz

  • Ming Tang

  • Mogana Sivalingam

  • Christian Thoma

  • Mark G. Lebwohl

Medical Centers

  • Department of Gynecological Oncology, University Hospital Basel, Basel, Switzerland

  • Department of Dermatology-Venereology, Hôpital Robert Debré, Reims, France

  • Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan

  • Dept of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

  • Department of Dermatology and Allergology, Ludwig-Maximilian-University Munich, Munich, Germany

  • Boehringer Ingelheim (China) Investment Co., Ltd, Shanghai, China

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

  • Boehringer Ingelheim International GmbH, Biberach, Germany

  • Icahn School of Medicine at Mount Sinai, New York, NY

Locations

  • Taiwan

  • Germany

  • China

  • France

  • United States

  • Japan

  • Switzerland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Dermatology

Disease

  • Psoriasis 14, pustular

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Multicenteric

  • Controlled

Phase

  • N/A

Study Id's

  • NCT03782792

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved